CCL21 (C-C Motif Chemokine Ligand 21)

Dysregulated lymphangiocrine signalling contributes to diseases including lymphedema, cardiovascular and metabolic disorders, neurodegeneration, and cancer. Finally, we discuss emerging strategies to restore lymphatic function in ageing tissues.

Except for the blank control group, the remaining 48 mice underwent ectopic transplantation of gastric cancer cells into the axilla and were randomly divided into four groups (n=12 per group): the gastric cancer group, the CIPN model group, the modified Danggui buxue decoction group, and Duloxetine group. Conclusion Modified Danggui buxue decoction may ameliorate pathological damage and pain symptoms in the dorsal root ganglia of a mouse model of oxaliplatin-induced peripheral neurotoxicity following gastric cancer chemotherapy. The mechanism is likely associated with the inhibition of the NF-κB signaling pathway in the dorsal root ganglia and the down regulation of ATM, NF-κB, CCL21, TNF-α, IL-1β, and IL-6 expression.

Moreover, distinct phosphorylation signatures within the serine/threonine clusters of the C-terminal tail of CCR7 were found to govern downstream signaling outcomes. Collectively, these results reveal a mechanism reliant on both disulfide bond stability and phosphorylation patterns through which hBD3 differentially regulates CCR7 function, providing novel insights into ligand-specific receptor modulation and potential therapeutic strategies for CCR7-mediated malignancies.

Notably, cytokine signatures in peripheral blood are emerging as prognostic biomarkers and predictive indicators for immune checkpoint blockade efficacy, particularly PD-1 inhibitors. This review systematically summarizes the current understanding of soluble mediator-driven mechanisms in NSCLC progression, including cytokines and chemokines, providing new opportunities for biomarker-guided precision therapy and combination strategies in NSCLC.

Clinically, higher CCL21 expression, elevated CCL21+ CAF signature scores, and stronger CCL21-CCR7 signatures in B cells were associated with favourable outcomes. Together, these data suggest that CCL21+ CAFs or CCL21 are potential prognostic biomarkers for risk stratification and immune microenvironment profiling and highlight the CCL21-CCR7 axis as a candidate pathway for therapeutic modulation of TLS maturity in PSCC.

Except for virus-induced immune exhaustion, distinct contributions to POD24 occurrence from malignant cells and immunosuppressive cell communities under distinct HBV infection states are discerned such as through CCL21/CCR7 signaling pathway. Taken together, our spatial multicellular dynamics reveal an increased prevalence of MBLM and variable FDC phenotypes which is associated with POD24 occurrence in HBV-related FL tumors.

The methylation status of the MLH1 promoter has limited value in predicting the prognosis of dMMR EEC. Molecular pathways heterogeneity between the methylated and nonmethylated subgroups suggests the necessity of integrate multi-dimensional indicators to optimize stratification strategies, instead of relying on a single epigenetic marker.

Through MR analysis, this study systematically identified 10 hub genes associated with AD and predicted 5 potential drug candidates. These findings offer novel insights into the molecular mechanisms underlying AD and may contribute to improved strategies for clinical diagnosis and targeted therapy.

Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.

Moreover, we observe a closer association of invasive than of non-invasive cancer cells with the lymphatic networks, which can be inhibited by blocking of CCL21. Our findings present a promising approach to investigate the cancer microenvironment, as our model can serve as a tool to study physiological lymphangiogenesis and pathological phenomena in vitro.

This integrative multi-cohort study uncovered common transcriptional and immune signatures underlying SjD, MALT lymphoma, and thyroid cancer. The identification of shared hub genes, particularly PLA2G7 and TGFB1I1, provides novel insight into the immune-driven transition from chronic inflammation to malignancy and offers promising biomarkers for cross-disease diagnosis and immunotherapeutic stratification. Key Points • Key genes (PLA2G7 and TGFB1I1) affecting the occurrence of Sjögren's syndrome, mucosa-associated lymphoid tissue lymphoma, and thyroid cancer are identified for the first time. • Bioinformatics methods were employed to simultaneously study three diseases for the first time.

Our results demonstrate that implantable FAST-LN rapidly induces tumor neoantigen-specific T cells in vivo, offering a promising strategy for neoantigen-based cancer immunotherapy.